Overview

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

Status:
Completed

Trial end date:
2020-10-20

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Loxo Oncology, Inc.

Treatments:

Midazolam
Pirtobrutinib